Targets

BRD4

9 articles

Computational & AIJournal of Chemical Theory and Computation

A restrained umbrella-sampling molecular dynamics protocol ranks molecular glue ternary complexes by stability and captures a key selectivity determinant that cheaper scoring methods miss

  • The authors built a molecular dynamics workflow that estimates ternary complex binding free energy by umbrella sampling along a geometric thermodynamic cycle, using conformational and orientational restraints to pull the complex apart.
  • It was tested retrospectively on interface point mutants of the CK1α–lenalidomide–CRBN complex, where predictions tracked experimental affinities closely, and on BRD4 degrader series engaging DCAF16, where the ranking agreed with biophysical assay trends.
  • The method explained BRD4 selectivity as dependent on one interfacial glycine, a result that faster MM/GBSA and HADDOCK scoring did not reproduce.
PointsBased on the abstract

Retrospective agreement on point mutants and two series is a low bar for a method this expensive: the question is whether it ranks within a congeneric glue series prospectively, where differences are small and cooperativity dominates. Umbrella sampling also hinges on the starting pose and restraint choices, so I'd want replicate runs and error bars. On my project I'd reserve it for a handful of shortlisted compounds, not triage.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Ugi chemistry turns ligand libraries into PROTACs for target-agnostic screening

  • A one-pot Ugi multicomponent reaction joins carboxylic-acid ligands to VHL ligand–linker conjugates in a single plate step, with solid-phase clean-up before cell assays.
  • A pilot library from seven diverse ligands was screened phenotypically in six cancer lines with no target chosen in advance.
  • Proteomics traced the best hit, a BI2536-derived degrader, to BRD4 degradation with clear selectivity over PLK1; NanoBRET and modeling supported ternary complex formation.
  • Ugi-built photoaffinity probes confirmed BRD4 as the direct binding partner.
PointsBased on the abstract

This flips the usual PROTAC workflow: degradation phenotype first, target second. The catch is the Ugi linker, which is stubby and amide-rich compared with optimized PROTAC linkers, so hits will likely be under-potent for many ligand classes. I'd feed it our orphan-ligand collection, then re-linker the survivors by conventional SAR.

Computational & AIJournal of Chemical Theory and Computation (ACS)

Umbrella-sampling free energies rank molecular glue ternary complexes

  • Molecular dynamics with umbrella sampling, run along a geometric thermodynamic cycle using conformational and orientational restraints, estimates how stable a glue-induced target–E3 ligase complex is.
  • Tested on CK1α–lenalidomide–CRBN interface mutants and on BRD4 degraders recruiting DCAF16.
  • Results tracked experimental affinities and biophysical trends, and explained BRD4 selectivity via one interfacial glycine, which MM/GBSA and HADDOCK scoring missed.
PointsBased on the abstract

Two E3 systems and a handful of mutants is a thin base for calling a protocol predictive, so I'd want a blind, prospective ranking on a chemotype it hasn't seen. Umbrella sampling per complex is also far costlier than MM/GBSA, and glue cooperativity depends on ternary-induced protein-protein contacts. On our own glue series, I'd first test whether it reproduces known SAR cliffs before spending GPU time.

Medicinal ChemistryBioorganic & Medicinal Chemistry

Aptamer-linked JQ1 conjugates offer a cell-free way to compare E2/E3 ubiquitination of BRD4

  • JQ1 was attached by click chemistry to a DNA aptamer that binds His tags, so any His-tagged E3 can be recruited to BRD4 without custom ligands.
  • In a reconstituted system, the conjugates drove BRD4 polyubiquitination with VHL complex, with a drop at high dose consistent with a hook effect.
  • Different E3 and E2 combinations gave distinct ubiquitin patterns; lysine-free ubiquitin and conjugate length helped separate chain growth from multi-site modification.
PointsBased on the abstract

As a tool compound this is attractive: swapping E3 ligands for a His-tag handle makes E3 comparisons ligand-free and clean. But a cell-free readout with a big DNA linker says little about real degraders, where ternary-complex geometry, permeability and linker length drive degradation. Next step: benchmark against a matched JQ1–VHL PROTAC (e.g., MZ1) in the same assay to see whether ubiquitination patterns track cellular DC50.

Medicinal ChemistryEuropean Journal of Medicinal Chemistry

Single-molecule VEGFR-2/BRD4 hybrid outperforms sorafenib plus JQ-1 in cell assays

  • A pharmacophore hybridization strategy fused sorafenib's aryl urea with the tetrahydropteridinone core of BI-2536 to give dual VEGFR-2/BRD4 inhibitors.
  • One lead from the analogue series showed broad antiproliferative activity and surpassed a sorafenib plus JQ-1 combination in cells.
  • Kinase profiling favored VEGFR-2, and in a xenograft model the lead outperformed both single agents.
PointsBased on the abstract

The hybrid logic is neat, but BI-2536 is known as a PLK1 inhibitor, so a PLK1 counter-screen would show how much of the cell potency comes from VEGFR-2 and BRD4. In vivo, a matched-exposure combination arm and tumor MYC knockdown as a BRD4 engagement readout would test whether "beats the combination" holds up.

Medicinal ChemistryChemMedChem

Three-armed PROTACs extend the MZ1 design for BET degradation in leukemia cells

  • On the MZ1-derived trivalent scaffold, the team built degraders with two JQ1 warheads and identical or different E3 recruiters to probe valency effects.
  • The top two degraded BRD2, BRD3 and BRD4 at low nanomolar concentrations in an AML line, one faster than the other.
  • Both also strongly curbed AML cell growth, in line with degradation, supporting a modular scaffold for tuning valency and E3 engagement.
PointsBased on the abstract

Two JQ1 warheads on an MZ1-derived core is a cheap way to buy avidity, but it needs to beat a well-tuned bivalent to count. Where are the matched MZ1/dBET controls, and does the extra mass cost permeability? The speed gap between the top two hints that ternary cooperativity, not just potency, is what the E3 swap changes.

Medicinal ChemistryJournal of Medicinal Chemistry

Dual PARP/BRD4 inhibitor D6 curbs tumor growth in breast cancer xenograft

  • Because BRD4 inhibition weakens homologous recombination repair, the authors built dual PARP/BRD4 inhibitors to make cancer cells more vulnerable to PARP blockade.
  • SAR optimization yielded D6, which inhibits both PARP1 and BRD4 in the low-nanomolar range and suppresses proliferation, colony formation and metastasis-related phenotypes in breast and pancreatic cancer cells.
  • D6 downregulates the BRD4-cJUN-CCL2 axis, reducing macrophage recruitment and macrophage-driven invasion.
  • In a breast cancer xenograft, D6 slowed tumor growth without evident toxicity.
PointsBased on the abstract

Two targets in one molecule looks elegant on paper, but balance is the hard part. Can one exposure hold both PARP1 and BRD4 engaged at tolerable doses, or does BRD4 occupancy drive toxicity? Before calling the pharmacophore merge a win, I need D6 compared with a PARP inhibitor plus BET inhibitor combination, and its selectivity across other bromodomains.

Medicinal ChemistrybioRxiv

Native MS Shows PROTAC Linker Length and Warhead Identity Shape Ternary Complexes Differently

  • Ion mobility, surface-induced dissociation and variable-temperature ESI were combined to probe BRD4–PROTAC–VCB complexes built with two BET ligands (JQ1 and I-BET726) and PEG linkers of different lengths.
  • Shorter linkers held complexes in more extended shapes; longer, flexible linkers allowed relaxed, native-like conformations.
  • JQ1 complexes tended to eject the PROTAC under collision, while tighter-binding I-BET726 complexes retained it; the two also melted differently.
PointsBased on the abstract

Linker optimization is still mostly empirical, so orthogonal readouts of how architecture shapes the complex interface are welcome. Gas-phase data are not solution cooperativity, and I'd not rank degraders by them alone, but pairing them with cellular degradation could help rationalize why two warheads behave so differently. A preprint, so treat the conclusions as provisional until peer review.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Hsc70-Recruiting Degraders Exploit Chaperone-Mediated Autophagy for Targeted Protein Degradation

  • Researchers developed Hsc70-Mediated Targeting Chimeras (Hsc70TACs), bifunctional small molecules that link an Hsc70-binding ligand to a ligand for a protein of interest, directing target degradation through chaperone-mediated autophagy rather than the ubiquitin-proteasome pathway used by PROTACs.
  • The approach is proposed to extend the range of degradable targets, including certain cytosolic and cell-membrane proteins, and to offer an alternative route that may help address resistance risks associated with proteasome-dependent degraders.
  • Degradation activity was demonstrated across multiple protein classes, including the transcriptional regulator BRD4, the regulatory protein MDM2, and the cell-membrane immune checkpoint protein PD-L1, across diverse cellular contexts.
  • A lead BRD4-directed compound, B-2, showed favorable pharmacokinetic behavior and produced robust BRD4 degradation in vivo, supporting continued development of the Hsc70TAC modality.
PointsBased on the abstract

A degradation route that bypasses CRBN/VHL entirely is worth my attention regardless of target — CMA recruitment sidesteps the ubiquitin-proteasome toolbox, so it should be orthogonal to the resistance mechanisms (neosubstrate mutation, E3 downregulation) that kill PROTAC leads in the clinic. PD-L1 is the result I'd chase: pulling a membrane protein through chaperone-mediated autophagy via LAMP2A translocation is something UPS-based PROTACs structurally can't do. My skepticism sits with the Hsc70 arm — KFERQ-motif engagement is promiscuous by design, so selectivity and off-target chaperone-client disruption need real scrutiny before I trust the SAR. B-2's in vivo PK and clean BRD4 knockdown at least de-risks synthesis/linker chemistry enough to treat this as a platform, not just a proof of concept.